Dr. Yukie Yoshii is the Founder and CEO of LinqMed Inc., a Japanese radiopharmaceutical start-up dedicated to developing innovative “Visible Cancer Therapeutics” using copper-64 (⁶⁴Cu). A biologist specializing in oncology and nuclear medicine, she brings over 20 years of experience in translational research, radiopharmaceutical development, and clinical implementation.Dr. Yoshii led the development of 64Cu-ATSM, a first-in-class radiotherapeutic targeting hypoxic tumors. She conducted extensive non-clinical studies and formulation work for its use in clinical settings. The Phase I trial (STAR-64) was the first-ever therapeutic study involving 64Cu-ATSM in humans and the first clinical trial of a domestically developed radiotherapeutic agent in Japan. The Phase III trial (STEP-64) for recurrent malignant glioma began in 2024 in collaboration with medical institutions.These efforts reflect her commitment to advancing dual-modality (theranostic) radiopharmaceuticals for unmet medical needs.In July 2022, she co-founded LinqMed Inc., building a team and facility to supply ⁶⁴Cu-based drugs and expand Japan’s theranostic capabilities globally. Under her leadership, LinqMed has raised over USD 30 million and formed partnerships with leading academic and industry collaborators.Passionate and people-focused, Dr. Yoshii is driven by the desire to help patients and healthcare workers by translating innovative science into accessible therapies.Her peer-reviewed publications are available at:https://pubmed.ncbi.nlm.nih.gov/?term=Yoshii+Yukie&size=50